research
Two Tumor Targets Fit Into One DNA-Delivered Dose
Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.
Summary
Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.
Wistar researchers reported a knob-into-hole antibody design delivered as DNA, allowing cells to produce bispecific T-cell engagers after dosing. A two-target version is intended to reduce escape when a tumor loses one antigen. The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients.
Why it matters
Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.
Limits and context
- The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients.
Key claims
Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.
Qualification: The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients.
Evidence: source-2026-07-18-003
Sources
- Wistar via Newswise: DNA-delivered ovarian cancer immunotherapyThe Wistar Institute via Newswise · official announcement
Corrections
No corrections have been recorded for this story.